- Faster delivery, efficient supply chain, and reduced cost for
NEW YORK, April 14 /PRNewswire/ -- Sumitomo Corporation of America (SCOA) has reached an agreement with Chiral Quest, Inc., a manufacturer and developer of chiral products using proprietary chiral technologies, for the distribution and sale of chiral products to the pharmaceutical industry.
Effective immediately, Sumitomo will be the exclusive sales agent for Chiral Quest in Japan and selected worldwide accounts.
More than 40 percent of the ethical drugs manufactured today utilize chiral intermediate technology. Chiral chemocatalysts play a key role in the manufacture of medicines, fine chemicals, agricultural chemicals, and flavors and fragrances.
"Chiral Quest is now in an expansion phase, and Sumitomo's international network of marketing and distribution facilities will enable us to provide our specialty chiral molecules quickly to pharmaceutical manufacturers globally at competitive prices," said Dr. Joseph Marasco, CEO of Chiral Quest. "This is a venture that will be welcomed by the chiral molecule marketplace, and will allow us to efficiently serve our growing client base."
Chiral Quest has wholly owned patents on a range of innovative chemical catalysts and processes used in the synthesis of chiral molecules. The company's primary laboratory and manufacturing facilities in New Jersey and China will now be supported by Sumitomo's extensive marketing capability and distribution network. Additional information on Chiral Quest is available at their website http://www.chiralquest.com/.
"Sumitomo has been a major supplier to the global pharmaceutical
industry for over the past four decades," noted Yasunori Ishibashi, senior
director of the SCOA Medical Sciences Group. "This collaboration makes it
possible for Sumitomo to play a significant rol
|SOURCE Sumitomo Corporation of America|
Copyright©2008 PR Newswire.
All rights reserved